Gilead Sciences Inc. will buy Kite Pharma Inc. for about $11.9 billion, making its biggest-ever deal for a breakthrough new cancer treatment that will help diversify away from its eroding franchise of medicines for hepatitis C infections.
With Kite, Gilead will gain a foothold in one of the most promising fields in oncology: treatments known as CAR-T that re-engineer the body’s own immune system to fight tumors. The drugmaker said Aug. 28 that it will pay $180 a share in an all-cash deal. That’s 29 percent above the closing price Aug. 25 for Kite.
“This is a pivot to cellular ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.